Capecitabina Zentiva Italia

Capecitabina Zentiva Italia is an oral, prescription‑only medication that contains the active ingredient capecitabine. It is supplied in tablet form (strength not specified) and is marketed in the European Union. Capecitabine is an antimetabolite chemotherapeutic agent that functions as a prodrug, converting to 5‑fluorouracil within tumor cells to interfere with DNA and RNA synthesis. The product is classified as a prescription drug (Rx) and is not a controlled substance.

Capecitabina Zentiva Italia is indicated for the treatment of certain advanced solid tumors, primarily in the metastatic setting.

- Metastatic colorectal cancer, often in combination with other chemotherapeutic agents. - Metastatic breast cancer, used as a single agent or with targeted therapies. - Off‑label use in gastric or pancreatic cancer may be considered under specialist supervision. - Adjuvant therapy for stage III colon cancer in patients who cannot receive intravenous 5‑fluorouracil.

The safety profile of capecitabine includes a range of adverse events that vary in frequency and severity.

Common: - Diarrhea or loose stools. - Nausea and vomiting. - Hand‑foot syndrome (palmar‑plantar erythrodysesthesia). - Fatigue or weakness.

Serious: - Severe neutropenia or leukopenia. - Cardiotoxicity, including chest pain or arrhythmias. - Severe allergic reactions such as Stevens‑Johnson syndrome.

Before initiating Capecitabina Zentiva Italia, clinicians should evaluate several patient‑specific factors to minimize risk.

- Assess renal and hepatic function; dose adjustments may be required in impairment. - Review pregnancy status; drug is contraindicated in pregnancy (Category D) and requires effective contraception. - Monitor complete blood counts regularly for signs of myelosuppression. - Evaluate for pre‑existing cardiac disease, as capecitabine can cause cardiotoxic effects. - Counsel patients on recognizing hand‑foot syndrome and report early skin changes. - Consider drug interactions, especially with anticoagulants and fluoropyrimidine‑enhancing agents.

Capecitabine may interact with other medicines, influencing its efficacy or safety.

Avoid: - Strong CYP2C9 inhibitors (e.g., fluconazole) that can increase capecitabine exposure. - Anticoagulants such as warfarin, which may heighten bleeding risk.

Use with caution: - Antacids or proton‑pump inhibitors that alter gastric pH and affect drug absorption. - Other fluoropyrimidines or cytotoxic agents, which can amplify myelosuppression. - Radiation therapy to the abdomen or pelvis, increasing risk of gastrointestinal toxicity.